Index

Note: Page numbers of article titles are in **boldface** type

ABSORPTION of amino acids and peptides from the intestine, **3–14**
  effects of dietary alterations and pyridoxine deficiency on, 10
  historical outline, 3–5
  relative rates of, 5–6
Aciduria, urocanic, 22–23
  organic acid and, major metabolic pathways associated with, 107–109
Albers–Schönberg disease, 134
Amino acid and peptide absorption, independence of, 6–7
Amino acids and peptides, absorption of from intestine, **3–14**
Amino acid metabolism—
  disturbances of in clinical syndromes not characterised by a primary amino acidopathy, **131–140**
  neonatal screening for inborn errors of, **153–165**
Amino acid screening, tests for, 154–157
  bacterial assay *vs* chromatography, 157
  bacterial assays, 154–155
  chromatography, 155–156
Aminoacidopathies in the newborn and unborn—
  diagnosis and management of inherited, **145–152**
  diagnostic tests, 146–147
  treatment, 147–151
Ammonia intoxication, congenital lysine intolerance with, 78–80
Anaemia in histidinaemia, 20
Ascorbic acid studies of cystinosis, 65
Ataxia in histidinaemia, 20
Ataxia telangiectasia syndrome, 138

BECKER muscular dystrophy, 135
Blackfan-diamond anaemia, 134
Blood, screening programs, 157–160
Blood diseases, disturbances of amino acid metabolism in, 134
Bone diseases, disturbances of amino acid metabolism in, 133–134

CAMPTODACTYLY with taurinuria, 139
Cerebral gigantism, 138
Choroid and retina, gyrate atrophy of, 137
Collagen disease, hydroxylysine-deficient, 83–84, 133
Congenital and acquired disturbances of histidine metabolism, **17–33**
Congenital lysine intolerance with ammonium intoxication, 78–80
Convulsions in histidinaemia, 17
Corneliade syndrome, 137–138
Cystathioninuria, 52–53
Cystinosis—
  benign, 61
  clinical features, 58–65
  diagnosis, 61–64
  history, 57–58
  hybridisation studies, 66
  late-onset, 60
  prenatal diagnosis, 65
  recent progress in our knowledge of, **57–67**
  treatment, 64–65
Cystinuria, peptide absorption in, 12–13

DE BARSY syndrome, 132
Dermatological diseases, disturbances of amino acid metabolism in, 131–133
Dermatoses, light, 132
Diphenylhydantoin, effect of administration of on histidine metabolism, 27–33
Duchenne's muscular dystrophy, 134–135

ENZYME maturation, prenatal, clinical importance of, 39–40
Erb-Landouzy muscular dystrophy, 136
Eye, diseases of the, disturbances of amino acid metabolism in, 137

FASCIO-SCAPULO-HUMERAL autosomal-dominant type juvenile dystrophy, 136
Formiminotransferase deficiency syndrome, 23–27

GIGANTISM, cerebral, 138

HARTNUP disease, peptide absorption in, 12–13
Histidinaemia, 17–22
  biochemical findings, 20–21
  clinical findings, 17–20
  treatment with low histidine diet, 21–22
Histidine metabolism—
  congenital and acquired disturbances of, **17–33**
  effect of diphenylhydantoin administration, 27–33
Homocystinuria—
  due to deficiency of cystathionine synthase activity, 41–51
  due to deficiency of 5-methyltetrahydrofolate methyltransferase activity, 51
  due to deficiency of 5,10-methylene tetrahydrofolate reductase activity, 52
Huntington chorea, 138–139
Hybridisation studies of cystinosis, 66
Hydroa vacciniforme, 132
β-Hydroxyisovalericaciduria, 121–123
Hydroxylysine metabolism, defects in, 81–84
Hydroxylysine-deficient collagen disease, 83–84
Hydroxylysinuria, 82–83
Hyperglycinaemia, identification of enzyme defect and its relation to ketonic, 118
Hyperlysinaemias, the hereditary, 74–80
Hypophosphatasia, hereditary, 133

ICHTHYONIS, congenital with atrophy and mental retardation, 132
Ichthyosis vulgaris, 132
Intestinal disease, peptide absorption in, 13–14
Intestine, absorption of amino acids and peptides from, **3–14**
Isovalericacidaemia, 109–111
  diagnosis of, 110–111
  family studies, 111
  metabolism of isovaleryl CoA in, 110
  treatment, 111

KERATOSIS follicularis spinulosa decalvans, 132
Kugelberg–Welander syndrome, 139

LATHYRISM-LIKE syndrome, 133–134
Leyden muscular dystrophy, 135
Limb-girdle type of dystrophy, autosomal-recessive, 135
Louis-Bar syndrome, 138
Lowe syndrome, 137
Lysine degradation, metabolic errors in, **71–85**
Lysine intolerance, congenital, with ammonia intoxication, 78–80

MCCUNE-ALBRIGHT syndrome, polyostotic fibrous dysplasia and, 134
Macular degeneration, hereditary, and aminoaciduria, 137
Marble bone disease, 134
Mental retardation and speech defects in histidinaemia, 17
Methionine metabolism in man—
  development and deficiencies, **37–54**
  metabolic effects associated with, 40–41
  α-Methyl-β-hydroxybutyric acidurias, 123–126
  metabolite excretion in, 125–126
  α-Methylacetoacetic acidurias, 123–126
  metabolite excretion in, 125–126
Methylacidurias, prenatal diagnosis, 117
Methylmalonicaciduria secondary to defects in B_{12} metabolism, 113–115
β-Methylcrotonylglycinuria, 121–123
Methylmalonic acidurias, 111–117
  investigation of, 116
  treatment, 116
Methylmalonyl CoA—
  abnormal metabolic interactions of, 117
  mutase defects, 113
  rasemose defects, 115–116
'Mitochondrial' myopathy, 136
Mucosal peptide uptake, role of, in protein absorption, 11–12
Mucosal transport, competition for between peptides, 7–8
Muscle, diseases of, and disturbances of amino acid metabolism, 134–136
Muscular dystrophies, 134–136
Myotonia dystrophica, 136

NEONATAL screening, for inborn errors of amino acid metabolism, **153–165**
  clinical significance, 162–163
  current programmes, 157–160
  frequency of disorders, 160–162
  pitfalls of, 164
  results of, 160–163
  tests for, 153, 157
Nephrotic cystinosis, 58–60
Netherton syndrome, 132

ORGANIC acid metabolism, inborn errors of, **107–127**
Organicacidaemias and acidurias, the major metabolic pathways associated with the, 107–109

PARKINSONISM, 139
Pelvic X-chromosomal-recessive type of dystrophy, infantile benign, 135
Peptide absorption—
in Hartnup disease and cystinuria, 12–13
in intestinal disease, 13–14
possible schemes of, 8–9
Peptides, competition for mucosal transport between, 7–8
Peptides and amino acids, absorption of from intestine, **3–14**
Phenylalaninaemia, 87–103
classification scheme, 93–99
dietary treatment, 99–102
diagnostic methods, 91–92
problems in classification and diagnosis, 89–91
urinary evaluation, 92–93
Phenylketonuria and other phenylalaninaemias, **87–103**
Pipecolicacidaemia, 80–81
Polyneuropathy, familial amyloidotic, 138
Polyostotic fibrous dysplasia and McCune-Albright syndrome, 134
Propionicacidaemia, 118–121
biotin-responsive, 119
inheritance and prenatal diagnosis, 120–121
Propionicacidaemia—(*continued*)
metabolic interactions in, 121
treatment, 120
Protein absorption, role of mucosal peptide intake in, 11–12
Pyridoxine deficiency, effects of dietary alterations and, on absorption of peptides and amino acids, 10
Pyroglutamicacidaemia, 126–127

RUBINSTEIN-TAYBI syndrome, 138

SACCHAROPINURIA, 76–78
Screening, for inborn errors of amino acid metabolism, **153–165**
Sjögren-Larsson syndrome, 130–131
Skin, syndromes with laxity of the, 132–133
Skin lesions, syndromes with ichthyosiform, 131–132
Small intestine, site of maximal absorption of amino acids and peptides along, 10
Speech defects in histidinaemia, 17
Sulphite oxidase deficiency disease, 53

TAURINURIA, camptodactyly with, 139

UROCANIC aciduria, 22–23

XERODERMA pigmentosum, 132

Index

Note: Page numbers of article titles are in **boldface** type.

ADENOMA, parathyroid, 216, 288–290

BIOSYNTHESIS of parathyroid hormone, **199–212**
Blood calcium, 323
Bone disease, forms of metabolic, 233
Bone formation, and hyperparathyroidism, 274–275
Bone porosity, hyperparathyroidism and, 272–273
Bone resorption, hyperparathyroidism and, 273–274
Bovine parathyroid hormone, 173–177
  structure of, 175–177
Breast, non-metastatic carcinoma of the, 246–249

CALCIFICATION, metastatic, 335
Calcium—
  blood, 323
  plasma:
    determination of in diagnosis of hyperparathyroidism, 228–230
    parathyroid tumours and, 219
  urinary, in hyperparathyroidism, 220
Calcium homeostasis, 218, 324–326
Carcinoma, parathyroid, 217, 290–291
Carcinoma of the breast, non-metastatic, 246–249
Cardiovascular abnormalities in hypocalcaemia, 337
Cataract, and hypoparathyroidism, 335
Chemistry of parathyroid hormone, the, **173–193**

ECTOPIC calcification, hyperparathyroidism and, 228
Ectopic parathyroid hormone syndrome, pseudohyperparathyroidism; hypercalcaemia of malignancy, **237–249**
Epilepsy, 333

GLANDULAR parathyroid hormone, 373
Growth retardation, in hypoparathyroidism, 335

HUMAN parathyroid hormone, 178–181
Hydrocortisone test in diagnosis of hyperparathyroidism, 230–231
Hypercalcaemia—
  non-parathyroid humoral, 245–246
  physical signs, 228
Hypercalcaemia of malignancy, 237–249
  with metastatic bone involvement, 237–238
  without metastases to bone, 238–239
Hypercalciuria, and hyperparathyroidism, 232
Hyperosteoidosis, 278–281
Hyperparathyroidism—
  adenoma vs. nodule, 297–298
  aetiology and pathogenesis, 220–221
  associated endocrine diseases and familial cases, 226
  bone histology and, **267–282**
  bone turnover, resorption and formation, 273–275
  clinical features, 222–228
  defect of bone mineralisation, 281–282
  diagnosis, 228–231
  differential diagnosis, 232–233
  double diagnosis, 233
  gastrointestinal symptoms, 225
  genetics of, 221
  hypercalcaemic symptoms, 225
  hypertension and, 226
  indications for exploration, 257–258
  localisation of adenoma, 258–260
  multivariate analysis in diagnosis of, 230
  neonatal hypocalcaemia and, 227
  plasma and urinary changes in, 219–220
  prevalence, 221–222
  primary, **215–233**, 287–294
    and hypercalcaemia, radioimmunoassay of parathyroid hormone in, 365–370

biochemical changes, 218–220
definitions and classification, 215
diagnosis of, 255
pathology, 216–217
(*see also* Surgery of primary hyperparathyroidism)
primary vs. tertiary, 298–299
primary nodular hyperplasia vs. secondary hyperplasia, 299
problems in the pathology of, 297–299
prognosis, 233
provocative tests, 231
psychiatric disorders and, 226
secondary, 295
tertiary, 295–297
timing of explorations, 258
Hyperparathyroidism of renal failure—
pathophysiology, 306–310
pathophysiology and treatment, **305–318**
rational approach to therapy, 313–315
suppressibility, 310–312
transplantation and, 316–317
Hyperplasia, 216
primary, 291
primary nodular (chief cell), 292–293
water-clear cell, 291–292
Hypertension, and hyperparathyroidism, 226
Hypocalcaemia—
and hypoparathyroidism, 232, **323–339**
causes of, 327
chronic, 327–331
clinical signs and symptoms, 332–337
differential diagnosis of, 337
drug-induced, 331
mechanisms producing, 326
neonatal, 227
neurological features, 333–337
radioimmunoassay of parathyroid hormone in, 370
treatment, 338–339
Hypoparathyroid states, management of the chronic, 338
Hypoparathyroidism, 299–300, 327–328
hypocalcaemia and, **323–339**
idiopathic, 328
new treatment possibilities, 339

IMMUNORADIOMETRIC assay, 359
Infants, hypoparathyroidism in, 339
Isolation of bovine parathyroid hormone, 173–175

JOINT disease, hyperparathyroidism and, 227

MAGNESIUM deficiency, 331
Mental changes in hypocalcaemia, 334
Myopathy, hyperparathyroidism and, 227

NEOPLASMS, in parathyroid glands, 328

OSTEITIS fibrosa, 217
and hyperparathyroidism, 223–225
histology of, 270–271
Osteolysis, 275

PAPILLOEDEMA, in hypocalcaemia, 334
Parathyroid activity, standard unit, 346–347
Parathyroid adenoma, 288–290
Parathyroid carcinoma, 290–291
Parathyroid glands—
infiltration of the, 328
nature of hormone released from, 200–203
pathology of the, **285–301**
Parathyroid hormone—
biological assay, 345–347
biosynthesis of, **199–212**
bovine, 173–177
chemistry, **173–193**
chemistry and assay of, 219
circulating, 373–378
conversion from prohormone to human, 206–207
discovery of, 203–205
end organ resistance to, 329–331
formation of from prohormone, 205–206
glandular, 373
human, 178–181
importance of amino-terminal residue, 185–186
labelling of, 352–353
measurement of, **345–380**
methionine residues and biological activity, 186–187
methods to recognise immunological fragments of, 378–380
physiological studies and the regulation of secretion of, 361–364, **389–409**
porcine, 177–178
purification of labelled, 353–355
radioimmunoassay of, 231, 347–380
reversible failure of, 331
'secreted' and 'circulating', 210–211
sequence and synthesis of, 188–191
structure-activity relationships, 181–188
synthesis of, 205–209
by non-parathyroid cancer in man, 207–209
synthetic fragments of human, 187–188

Parathyroid hormone metabolites, chemical studies of, 191–193
Parathyroid hormone molecule, biologically active region of, 183–185
Parathyroid hormone syndrome, ectopic, 239–245
Parathyroid insufficiency, partial, 328
Parathyroid tissue, histological change in, 255–257
Parathyroid tumours, age and sex, 222
Parkinsonism, 334
Phosphatase, plasma alkaline, in hyperparathyroidism, 220
Phosphorus—
in diagnosis of hyperparathyroidism, 230
in hyperparathyroidism, 219
Porcine parathyroid hormone, 177–178
Physiology of parathyroid hormone, **389–409**
Primary nodular (chief cell) hyperplasia, 292–293
Pseudohyperparathyroidism, 240–241
Pseudohypoparathyroidism, 329–330
Pseudopseudohypoparathyroidism, 330

RADIOIMMUNOASSAY of parathyroid hormone, 347–380
heterogeneity of parathyroid hormone, 372–380
in clinical conditions in man, 365–372
incubation conditions, 355–356
methodology, 349–359
production of antisera, 349–351
separation of antibody bound from free unbound hormone, 357–358
standards for, 359–361
utilisation of the, 361–372

Renal disorders, and hyperparathyroidism, 222–223
Renal failure—
chronic, 331
and hyperparathyroidism, radioimmunoassay of parathyroid hormone in, 370–372
the hyperparathyroidism of, **305–318**

SKELETAL changes in hypoparathyroidism, 336
Skin, in hypocalcaemia, 334
Spinal abnormalities in hypocalcaemia, 334
Steatorrhoea, 331
in hypocalcaemia, 335
Surgery of primary hyperparathyroidism, **253–265**
effects of rendering patients euparathyroid, 254–255
permanency of correction, 253–254
postoperative management, 264–265
results of operation, 253–255
technique of operation, 263
the operation, 260–263

TEETH, in hypoparathyroidism, 336
Tentary, 332–333
Thyroidectomy, post, 327–328

VITAMIN D deficiency, 330–331
Vitamin deficiency states, management of the, 339

WATER-CLEAR cell hyperplasia, 291–292

Index

Note: Page numbers of article titles are in **boldface** type.

ACTH levels, plasma, in Cushing's disease, 569–570
ACTH screening tests—
  prolonged, in Addison's disease, 573–575
  rapid, in Addison's disease, 572–573
ACTH test, long, 486
Addison's disease, 572–576
  aetiology of, 575–576
  x-ray examinations, 575
ADH secretion, the syndrome of inappropriate, 499–501
Adrenal cortex (excluding aldosteronism), **557–587**
  biosynthesis of hormones, 557–558
  normal physiological control, 558
  physiology, 557–561
  plasma steriod concentrations, 559–560
  variations in plasma steriod levels throughout day, 560–561
Adrenal hyperplasia, congenital, 576–581
  antenatal diagnosis of, 580
  control and treatment, 580–581
  diagnosis of, 580
Adrenocortical disorders, notes on analytical techniques used in investigation of, 581–587
Adrenocortical insufficiency, 572
  treatment of, 576
Arginine test, 490
Amenorrhoea—
  associated with hypogonadism, 544–546
  associated with virilising symptoms, 547–548
  with galactorrhoea, 546–547
  with gonadal deficiency, 548–549
Amenorrhoea, primary—
  investigation of, 540–544
  with normal secondary sexual characteristics, 540–541
  with hypogonadism, 541–544
Amenorrhoea, secondary, investigation of, 544
Androgen deficiency, 514–518
Androgen secretion, investigation of, 540
Androgens, measurement of, 508–509
Ankle tendon reflex duration, 432
Antibodies, thyroid, 434–436

BLOOD sugar, and acromegaly, 476
Bone, x-rays, in hyperparathyroidism, 463
Bone disease, 468
Bone morphology, in hyperparathyroidism, 463–464
Bovril test, 490

CALCIUM, 451–457
  fractions of in plasma, 451–453
  implications of protein-binding of, 453–455
  serum, investigation of in acromegaly, 482
  tubular reabsorption of, 465
  urinary, investigations in acromegaly, 482
  use of protein values to interpret total, 453–455
Calcium, measurement—
  of ionised, 455
  of ultrafiltrable or diffusible, 455
  practical aspects of, and interpretation, 456–457
Clomiphene stimulation test, 512
Clomiphene test, 487–488, 534
Corticosteroids, basal urinary, in Cushing's disease, 563–564
'Cortisol' levels, plasma—
  in Addison's disease, 572
  in Cushing's disease, 562
Cortisol secretion rate, in Addison's disease, 569
Cushing's syndrome, 561–571

DEPOT-TETRACOSACTRIN injections, in Addison's disease, 573
Dexamethasone suppression test, overnight, in Cushing's disease, 562–563
Diabetes insipidus—
  and pituitary function, 482
  cranial, 496–499
  partial, 499

Dwarfism—
and systemic diseases, 494
investigation of, 492–494
laron type, 494

ELECTROCARDIOGRAM, and thyroid failure, 432
Electrolyte levels, plasma, in Cushing's disease, 570
serum, in Addison's disease, 572
Euthyroidism with thyroid autonomy, 440–441

GALACTORRHOEA, 494–495
Gigantism and acromegaly, investigation of, 476–482
radiological, 477–480
Glucagon test, 489–490
Glucose tolerance test, 476
Gonadal deficiency, amenorrhoea with, 548–549
Gonadal dysfunction, female, **533–554**
Gonadal dysfunction, male, **507–530**
clinical aspects, 507–508
hormone measurements, 508–514
Gonadotrophin releasing hormone test, 513–514
Gonadotrophin secretion, investigation of, 533–537
Gonadotrophins—
human chorionic, tests of, 511–512
measurement of, 509
Goitre, 443–448
fixed multinodular, 445–446
simple non-toxic, 446
solitary thyroid nodule, 445
with hyperthyroidism, 446
Graves' disease, ophthalmic, 440–441
Growth hormone—
and gigantism, 476
peripheral tissues, non-responsiveness to, 494
Growth hormone release, assessment of, 489–490
Gynaecomastia, 527–529

HYDROCORTISONE test, 466
Hyperaldosteronism, primary, **593–607**
adrenal adenoma and bilateral renal artery stenosis, 602–603
clinical features, 593
differential diagnosis, 603–606
excess of corticosterone, deoxycorticosterone or 18-hydroxycorticosterone, 601–602
investigations of, 593–596
response to spironolactone, 600–601
sodium balance studies, 596–600
Hypercalcaemia, 465–469
Hypercalcaemic nephropathy, chronic, 467–468
Hyperparathyroidism—
assessment of the bones in, 462–464
plasma alkaline phosphatase, 464
primary, 465–469
x-rays of hand, 462–463
Hyperthyroidism—
due to solitary toxic nodule, 440
goitre with, 446
in malignant disease, 440
secondary to increased TSH production, 440
suspected, 438–441
Hypogonadism—
amenorrhoea associated with, 544–546
postpubertal, 517–518
Hypoparathyroidism, 469–472
idiopathic, differentiation of from pseudohypoparathyroidism, 471–472
Hypopituitarism, 482–492
Hypopituitary dwarfism, acquired, 493–494
Hypothalamic-hypophyseal-gonadal axis, 533–540
Hypothalamic-pituitary-adrenal function, 483–486
Hypothalamic-pituitary function, investigation of, 480–482
Hypothalamic-pituitary-gonadal function, 487–489
Hypothalamic-pituitary-thyroid function, 486–487
Hypothalamus and pituitary gland, diseases of the, **475–501**
Hypothyroidism, suspected, 441–442

IMPOTENCE, 526–527
Infertility—
female, investigation of, 549–551
male, 518–526
Insulin tolerance test, 485, 489
in Cushing's syndrome, 569
in hypothalamic-pituitary function investigations, 480–481
Iodine, protein-bound, 426–427

KARYOTYPE, and spermatogenesis, 522
Karyotyping, for congenital hyperplasia, 580

LH/FSH-RH test, 537
standard, 488–489
Luteal deficiency, infertility due to, 551

Luteal phase, investigation of, 539
Lysine-vasopressin test, 485–486

MENSTRUAL cycle, FSH and LH levels during, 534
Metyrapone test, in Cushing's disease, 568–569

OESTROGEN administration, 534–537
Oestrogen deficiency, infertility due to, 549–551
Oestrogen secretion, investigation of, 537–538
Oestrogens, measurement of, 510
Ophthalmic Graves' disease, 440–441
Ovarian function, investigation of, 537–540
Ovulation, infertility with absent, 551

PARATHYROID function, recovery of, 470
Parathyroid glands, investigation of disorders of, **451–472**
Parathyroid hormone, 457–462
  interpretation of assay results, 459–460
  methods of expressing quantity of, 457–458
  radioimmunoassay of, 457
  relationship of level of to plasma calcium, 461
  relationship of metabolism to biological and immunological activity, 458–459
  stimulation and suppression tests, 462
  tests based on actions of, 464–465
Phaeochromocytoma, **609–616**
  diagnosis, 613–616
  natural history and manifestations, 612–613
  pathophysiology, 610–611
Phosphate—
  plasma, and tubular reabsorption of, 464–465
  serum, investigation of in acromegaly, 482
Phosphate deprivation, 467
Photonabsorptiometry, 463
Pituitary fossa, radiological investigations of, 477
Pituitary function—
  basal, 480
  dynamic tests of, 511–514
Pituitary gland—
  diseases of the hypothalamus and, 475–501
  investigation of diseases of posterior, 495–501
Pneumoencephalography—
  and acromegaly, 477–479
  side-effects, 479
Prolactin—
  and acromegaly, 476
  measurement of, 510
Prolactin release, assessment of, 490–491
Protein-bound iodine, 426–427
Puberty, delayed, and androgen deficiency, 514–517
Puberty, precocious, 529–530
  investigation of in female, 553–554

RADIOIODINE kinetic studies, 437–438
Radiological investigations, in Cushing's disease, 571
Radiology, in investigation of thyroid disease, 438
Renal stones, calcium-containing, 465–467

SCANNING—
  thyroid, 436–437
  ultrasonic, 438
Screening tests, ACTH, in Addison's disease, 572–575
Scintigraphy, thyroid, 436–437
Semen analysis, 520–522
Serum lipid levels, 432
Serum thyrotrophin, 432–433
Serum thyroxin, 427
Serum triiodothyronine, 427–428
Sexual precocity, investigation of female, 551–554
Skin and soft tissues, and acromegaly, 479–480
Sperm antibodies, 525
Spermatogenesis—
  defective, 518
    investigations into causes of, 519–526
    hormonal measurements, 522
    karyotype and, 522
    radiological examination, 523
Stimulation tests, in Cushing's disease, 564–566
Suppression tests, in Cushing's disease, 566–568

TESTICULAR biopsy, 523–525
Tetracosactrin infusion, in Addison's disease, 574–575
Thiazide challenge, 467
Thyroid antibodies, 434–436
Thyroid biopsy, 437
Thyroid disease, investigation of, 438–448
Thyroid dysfunction, tests to establish cause of, 434–438
Thyroid function tests, classification and description of, 426–438

Thyroid function tests—(*continued*)
circulating levels of free thyroid hormone, 429–430
dynamic tests, 430–432
tests of hypothalamic-pituitary function, 432–434
tests of peripheral tissue function, 432
tests to establish the level of thyroid function, 426–434
thyroid hormone, total circulating levels, 426—429
Thyroid gland, diseases of the, **425–448**
Thyroid hormone binding tests, 428–429
Thyroid scanning and scintigraphy, 436–437
Thyroid-releasing hormone test, standard, 487
Thyroidal uptake of ^{131}I, 430–431
Thyrotoxicosis, triiodothyronine, 438–439
Thyrotrophin, serum, 432–433
Thyrotrophin-releasing hormone test, 433–434
Thyrotrophin stimulation test, 431–432
Thyroxin, serum, 427
Thyroxin index, free, 429
Thyroxin ratio, effective, 429–430
Triiodothyronine—
free, 429
serum, 427–428
urinary, 430
Triiodothyronine suppression test, 431
Triiodothyronine thyrotoxicosis, 438–439

ULTRASONIC scanning, in thyroid dysfunction, 438

VASO-EPIDIDYMOGRAPHY, 525
Visual fields, and acromegaly, 476–477

WATER deprivation test, in cranial diabetes insipidus, 497–499
Water load test, 500, 501

X-RAY examination, in gigantism and acromegaly, 480, 481

INDEX

31
3–439

ysfunc-

477

diabetes

m and